pH-Responsive Polymer for Tumor-Specific Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing polymers with stealth properties for drug delivery suppress interactions with both normal tissue and tumor tissue, leading to inefficient drug accumulation and incorporation in cancer cells.
Innovation Solution
A pH-responsive polymer that remains electrically neutral at pH above 7 but becomes cationic at pH 7 or lower, specifically interacting with tumor tissue while avoiding normal tissue, is developed. This polymer is biocompatible, biodegradable, and includes groups such as carboxyl, sulfo, or phosphonic groups, with a weight-average molecular weight of 1,000 to 200,000, allowing efficient drug delivery to tumor sites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a stealth polymer (e.g., PEG) is used to suppress interaction with blood components and normal tissue, then blood retention and toxicity suppression are improved, but drug accumulation and incorporation into tumor tissue deteriorate
Solution Approach 1:
The polymer's charge state is made dynamic and pH-dependent. At physiological pH (7.4), the polymer maintains a neutral state for stealth properties. At tumor tissue pH (6.5-6.8), the polymer transitions to a cationic state to enhance cellular uptake. This dynamic charge transition resolves the contradiction between stealth and tumor accumulation.
Solution Approach 2:
The invention changes the charge parameter of the polymer based on pH conditions. By incorporating pH-responsive groups (carboxyl, sulfo, or phosphonic groups) that transition from neutral to cationic at lower pH, the polymer adapts its electrostatic properties to different microenvironments, achieving both stealth in blood and enhanced accumulation in tumor tissue.
2Object-affected harmful factors
If a polymer maintains electrical neutrality to avoid interaction with normal tissue, then biocompatibility is improved, but interaction with and incorporation into tumor cells deteriorates
Solution Approach 1:
The polymer exhibits different charge qualities in different locations (pH environments). In normal tissue (pH 7.4), it maintains neutrality to minimize harmful interactions. In tumor tissue (pH 6.5-6.8), it becomes cationic to enhance cellular incorporation. This local quality differentiation resolves the contradiction between biocompatibility and tumor cell uptake.
Solution Approach 2:
The invention exploits the harmful acidic microenvironment of tumor tissue (pH 6.5-6.8) as a beneficial trigger. The low pH that characterizes tumor pathology is converted into a signal that activates the polymer's cationic state, enhancing tumor cell uptake while maintaining neutrality in normal physiological conditions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The pH-responsive polymer effectively accumulates and incorporates drugs into tumor cells while minimizing damage to normal tissues, enhancing the stealth property and drug delivery efficiency to tumor tissues.
Implementation Method 1
a group which is electrically neutral under pH environments of more than 7 and which changes to be cationic at pH 7 or less
Data Source
AI summary
A pH-responsive polymer formed of a biocompatible polymer to which a group which is electrically neutral under pH environments of more than 7 and which changes to be cationic at pH 7 or less is bonded.